Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
Portfolio Pulse from Avi Kapoor
Wall Street's most accurate analysts have spotlighted three high-dividend-yielding health care stocks: Royalty Pharma (RPRX), Johnson & Johnson (JNJ), and Medtronic (MDT). Analysts have provided updated ratings and price targets for these stocks, which are known for their high free cash flows and substantial dividend payouts.
June 12, 2024 | 1:15 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Medtronic (MDT) has received updated ratings from top analysts. Wells Fargo maintained an Overweight rating and increased the price target to $105, while Truist Securities maintained a Hold rating and reduced the price target to $88. Recent news includes a recall of some StealthStation S8 applications.
The mixed ratings and price targets indicate uncertainty. The recent recall could have a negative impact, but the increased price target by Wells Fargo suggests some optimism.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 80
NEUTRAL IMPACT
Royalty Pharma (RPRX) has received updated ratings from top analysts. B of A Securities maintained a Buy rating but cut the price target to $38, while JP Morgan maintained an Overweight rating and reduced the price target to $42. Recent news includes a $1.5 billion senior unsecured notes offering.
The updated ratings and price target reductions indicate mixed sentiment. The recent $1.5 billion notes offering could provide liquidity but also suggests potential financial adjustments.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Johnson & Johnson (JNJ) has received updated ratings from top analysts. Cantor Fitzgerald reiterated an Overweight rating with a $215 price target, while Morgan Stanley maintained an Equal-Weight rating and slightly reduced the price target to $167. JNJ is set to review Q2 results on July 17.
The reiterated Overweight rating and upcoming Q2 results review suggest positive sentiment. The slight price target reduction by Morgan Stanley is not significant enough to outweigh the overall positive outlook.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 80